Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
ABC Transporters: Importer01:27

ABC Transporters: Importer

ATP-binding cassette or ABC transporters are a class of ATP-driven pumps that hydrolyze ATP to move solutes across the membrane. They can be grouped into importers and exporters. While exporters are present in all domains of life, importers exist only in bacteria and some plants.
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
The Significance of Membrane Transport01:44

The Significance of Membrane Transport

The transport of solutes across the cell membrane is essential for metabolic processes, like maintaining cell size and volume, generating the action potential, exchanging nutrients and gases, etc. Membrane transport can be either passive or active. It can be simple diffusion, facilitated, or mediated transport aided by transport proteins such as transporters and channels.
Transporters facilitate either an active or passive movement of solutes. They can allow a single-molecule transport down its...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A high amylose to amylopectin ratio in a low-protein diet promoted growth performance and protein deposition of breast muscle in geese.

Animal nutrition (Zhongguo xu mu shou yi xue hui)·2026
Same author

Refined AI-ASPECTS with modified atlas and lesion-load thresholds: advancing acute ischemic stroke imaging and prognostic prediction.

BMC medicine·2026
Same author

Evaluation of N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) as a Prognostic Marker in Patients With Acute Heart Failure in the Emergency Department.

Cureus·2026
Same author

Effects of Dietary Sulphur Amino Acid Levels on Growth Performance, Meat Quality, Nutrient Digestibility, Serum Biochemistry and Feather Follicle Transcriptomics in Jiangnan White Goslings.

Animals : an open access journal from MDPI·2026
Same author

Ticks and Tick-Borne Microorganisms in Australian Wildlife: A Scoping One Health Evidence Synthesis of Reported Associations and Knowledge Gaps.

Pathogens (Basel, Switzerland)·2026
Same author

A national survey of gastrointestinal nematodes in Australian dairy goats using faecal egg counts and deep amplicon sequencing.

Current research in parasitology & vector-borne diseases·2026

Related Experiment Video

Updated: Jul 4, 2026

ABCG5/G8 Crystallization in a Lipidic Bicelle Environment for X-Ray Crystallography
06:47

ABCG5/G8 Crystallization in a Lipidic Bicelle Environment for X-Ray Crystallography

Published on: August 25, 2023

ABCG2 transporter: Structural and functional associations with gout (Review).

Muhammad Arslan Asif1, Zeshan Zulfiqar1, Bahar E Mustafa2

  • 1Department of Animal Nutrition and Feed Science, College of Animal Science and Technology, Henan Agricultural University, Zhengzhou, Henan 450000, P.R. China.

International Journal of Molecular Medicine
|July 3, 2026
PubMed
Summary
This summary is machine-generated.

Dysfunctional ATP-binding cassette sub-family G member 2 (ABCG2) impairs urate excretion, increasing gout risk. The Q141K variant reduces urate transport, impacting treatment response and necessitating novel therapeutic strategies.

Keywords:
ATP‑binding cassette sub‑family G member 2gouthyperuricemiapharmacogenomics

More Related Videos

Demonstration of Heterologous Complexes formed by Golgi-Resident Type III Membrane Proteins using Split Luciferase Complementation Assay
05:28

Demonstration of Heterologous Complexes formed by Golgi-Resident Type III Membrane Proteins using Split Luciferase Complementation Assay

Published on: September 10, 2020

Related Experiment Videos

Last Updated: Jul 4, 2026

ABCG5/G8 Crystallization in a Lipidic Bicelle Environment for X-Ray Crystallography
06:47

ABCG5/G8 Crystallization in a Lipidic Bicelle Environment for X-Ray Crystallography

Published on: August 25, 2023

Demonstration of Heterologous Complexes formed by Golgi-Resident Type III Membrane Proteins using Split Luciferase Complementation Assay
05:28

Demonstration of Heterologous Complexes formed by Golgi-Resident Type III Membrane Proteins using Split Luciferase Complementation Assay

Published on: September 10, 2020

Area of Science:

  • Biochemistry and Molecular Biology
  • Genetics and Genomics
  • Physiology and Pathophysiology

Background:

  • ATP-binding cassette sub-family G member 2 (ABCG2) is crucial for urate homeostasis.
  • ABCG2 dysfunction is a significant genetic risk factor for hyperuricemia and gout.
  • ABCG2 acts as a high-capacity urate efflux pump in key organs.

Purpose of the Study:

  • To review the molecular structure, physiological functions, and pathophysiological effects of ABCG2.
  • To focus on the common Q141K loss-of-function variant and its impact on urate transport and disease risk.
  • To explore ABCG2's role in the urate transportome and its novel regulatory mechanisms.

Main Methods:

  • Literature review of ABCG2's structure, function, and genetics.
  • Analysis of the Q141K variant's impact on protein stability, trafficking, and urate transport.
  • Exploration of ABCG2 interactions with other transporters and regulatory factors like the gut microbiome.

Main Results:

  • The Q141K variant impairs ABCG2 stability and urate transport, elevating gout and cardiorenal comorbidity risk.
  • ABCG2 interacts dynamically with other urate transporters and is regulated by gut microbial metabolites.
  • Q141K carriers show diminished efficacy with uricosuric drugs, highlighting pharmacogenomic implications.

Conclusions:

  • Understanding ABCG2's multifaceted role is key to addressing impaired urate excretion.
  • Emerging therapies like ABCG2 activators and microbiome modulators offer personalized gout prevention and treatment.
  • Targeted strategies focusing on ABCG2 are essential for managing hyperuricemia and gout.